ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
2024년과 2029년, 인도는 세계에서 가장 많은 저혈당증 신규 진단 환자 수를 기록할 것으로 예상되며, 이는 전 세계 환자의 대부분을 차지할 것으로 예측됩니다.
Novo Nordisk의 GlucaGen(glucagon hypokit)과 Eli Lilly의 Glucagon은 수십년 동안 시판된 주요 글루카곤 제제였습니다.
저혈당 치료제 파이프라인에는 16개의 분자가 포함되어 있으며, 등록 전 단계의 자산은 없으며, 3개의 자산은 3상 개발 단계에 있고, 4개의 자산은 2상 단계에 있습니다.
지난 10년간 저혈당증에 대한 217건의 임상시험이 진행되었습니다. 가장 많은 연구가 시작된 해는 2019년(32건)이며, 2018년(30건)이 그 뒤를 이었습니다.
지난 24개월 동안 저혈당 치료제를 개발하는 기업과 관련된 3건의 전략적 제휴와 4건의 인수합병이 완료되었습니다.
세계의 저혈당증 시장에 대해 조사 분석했으며, 질병 상황, 시판 중인 의약품 및 파이프라인 의약품 평가, 현재와 미래경쟁 구도 등의 정보를 전해드립니다.
목차
제1장 서문
제2장 주요 조사 결과
제3장 질환 상황
질환 개요
역학 개요
치료 개요
제4장 출시 약품 평가
주요 출시 약품
개요 : 작용기전별
개요 : 분자 유형별
제품 개요와 판매 예측
제5장 가격 결정과 상환 평가
연간 치료비
가격 결정과 상환까지 시간
제6장 파이프라인 의약품 평가
중기-후기 단계 파이프라인 의약품
개요 : 개발 단계별
개요 : 작용기전별
개요 : 분자 유형별
약품 고유 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
치료 영역과 적응증 고유 PTSR과 LoA
제7장 임상시험 평가
과거 개요
개요 : 단계별
개요 : 현황별
개요 : 단계별(진행중/계획된 임상시험)
가상 컴포넌트에 의한 시험
시험 개요 : 지역별
단일국/다국간 시험 : 지역별
스폰서 주요 20개사와 내역 : 단계별
스폰서 주요 20개사와 내역 : 현황별
개요 : 엔드포인트 현황별
개요 : 인종/민족별
등록 데이터
시험 시설 주요 20개국
세계의 주요 20개 시설
실현 가능성 분석 - 지역 개요
실현 가능성 분석 - 벤치마크 모델
제8장 거래 상황
합병, 인수, 전략적 제휴 : 지역별
최근 합병, 인수 및 전략적 제휴
제9장 상업적 평가
주요 시장 기업
제10장 향후의 시장 촉매
제11장 부록
LSH
영문 목차
영문목차
This reports provides a data-driven overview of the current and future competitive landscape in Hypoglycemia Therapeutics.
In 2024 and 2029, India is estimated to have the highest number of diagnosed incident cases of hypoglycemia, representing a large portion of global cases.
Novo Nordisk's GlucaGen (glucagon hypokit) and Eli Lilly's Glucagon had been the primary marketed glucagons for decades.
The hypoglycemia pipeline holds 16 molecules, with no assets in the pre-registration stage, three assets in Phase III development, and another four in
Phase II.
Over the past decade, 217 clinical trials have been conducted in hypoglycemia. The year with the most studies initiated was 2019, with 32 trials, followed by 2018 with 30 trials.
During the past 24 months, three strategic alliances and four mergers and acquisitions involving companies developing hypoglycemia assets have been completed.
Scope
GlobalData's Hypoglycemia: Market View combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include -
Disease Landscape
Disease Overview
Epidemiology Overview
Treatment Overview
Marketed Products Assessment
Breakdown by Mechanism of Action, Route of Administration
Product Profiles with Sales Forecast
Pricing and Reimbursement Assessment
Annual Therapy Cost
Time to Pricing and Time to Reimbursement
Pipeline Assessment
Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
Product Profiles with Sales Forecast
Late-to-mid-stage Pipeline Drugs
Phase Transition Success Rate and Likelihood of Approval
Clinical Trials Assessment
Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
Enrolment Analytics, Site Analytics, Feasibility Analysis
Deals Landscape
Mergers, Acquisitions, and Strategic Alliances by Region
Overview of Recent Deals
Commercial Assessment
Key Market Players
Future Market Catalysts
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Hypoglycemia Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Hypoglycemia Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Table of Contents
1 Preface
1.1 Contents
1.2 Report Scope
1.3 List of Tables and Figures
1.4 Abbreviations
2 Key Findings
3 Disease Landscape
3.1 Disease Overview
3.2 Epidemiology Overview
3.3 Treatment Overview
4 Marketed Drugs Assessment
4.1 Leading Marketed Drugs
4.2 Overview by Mechanism of Action
4.3 Overview by Molecule Type
4.4 Product Profiles and Sales Forecast
5 Pricing and Reimbursement Assessment
5.1 Annual Cost of Therapy
5.2 Time to Pricing and Reimbursement
6 Pipeline Drugs Assessment
6.1 Mid-to-late-stage Pipeline Drugs
6.2 Overview by Development Stage
6.3 Overview by Mechanism of Action
6.4 Overview by Molecule Type
6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
6.6 Therapy Area and Indication-specific PTSR and LoA
7 Clinical Trials Assessment
7.1 Historical Overview
7.2 Overview by Phase
7.3 Overview by Status
7.4 Overview by Phase for Ongoing and Planned Trials
7.5 Trials with Virtual Components
7.6 Overview of Trials by Geography
7.7 Single-Country and Multinational Trials by Region
7.8 Top 20 Sponsors with Breakdown by Phase
7.9 Top 20 Sponsors with Breakdown by Status
7.10 Overview by Endpoint Status
7.11 Overview by Race and Ethnicity
7.12 Enrollment Data
7.13 Top 20 countries for Trial Sites
7.14 Top 20 Sites Globally
7.15 Feasibility Analysis - Geographic Overview
7.16 Feasibility Analysis - Benchmark Models
8 Deals Landscape
8.1 Mergers, Acquisitions, and Strategic Alliances by Region
8.2 Recent Mergers, Acquisitions, and Strategic Alliances
